Feedback
Settings

Settings

Goto Application

1. WO2008016404 - PARATHYROID HORMONE ANALOGUES AND USES THEREOF

PermaLink
Publication Number WO/2008/016404
Publication Date 07.02.2008
International Application No. PCT/US2007/010720
International Filing Date 02.05.2007
IPC
A61K 38/29 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
22Hormones
29Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
A61K 38/12 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
12Cyclic peptides
A61K 9/08 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
08Solutions
A61P 19/08 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
19Drugs for skeletal disorders
08for bone diseases, e.g. rachitism, Paget's disease
CPC
A61K 38/29
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
22Hormones
29Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
A61K 47/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
08containing oxygen, ; e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
A61K 47/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
08containing oxygen, ; e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/18
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
16containing nitrogen, ; e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
A61K 9/0019
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
0012Galenical forms characterised by the site of application
0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
A61K 9/0075
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
0012Galenical forms characterised by the site of application
007Pulmonary tract; Aromatherapy
0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy;
0075for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
Applicants
  • ZELOS THERAPEUTICS, INC. [US]/[US] (AllExceptUS)
  • MORLEY, Paul [CA]/[CA] (UsOnly)
  • STOGNIEW, Martin [US]/[US] (UsOnly)
  • MACDONALD, Brian [US]/[US] (UsOnly)
  • MERUTKA, Gene, Scott [US]/[US] (UsOnly)
  • PALEPU, Nagesh, R. [US]/[US] (UsOnly)
Inventors
  • MORLEY, Paul
  • STOGNIEW, Martin
  • MACDONALD, Brian
  • MERUTKA, Gene, Scott
  • PALEPU, Nagesh, R.
Agents
  • ELRIFI, Ivor, R.
Priority Data
11/517,14606.09.2006US
11/650,91805.01.2007US
60/834,98031.07.2006US
60/837,97215.08.2006US
60/905,69307.03.2007US
60/925,63920.04.2007US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) PARATHYROID HORMONE ANALOGUES AND USES THEREOF
(FR) ANALOGUES DE L'HORMONE PARATHYROÏDIENNE ET LEURS PROCÉDÉS D'UTILISATION
front page image
Abstract
(EN)
The present invention is directed to novel methods of treating a subject with a bone deficit disorder. The methods generally include administering to a subject in need thereof a pharmaceutically acceptable formulation comprising a parathyroid hormone (PTH) peptide analogue in a daily dose sufficient to result in an effective pharmacokinetic profile and maintained adenylate cyclase activity, while simultaneously reducing undesirable side effects.
(FR)
L'invention concerne de nouveaux procédés de traitement d'un patient présentant un trouble de déficience osseuse. Ces procédés consistent généralement à administrer à un patient nécessitant un tel traitement une formulation pharmaceutiquement acceptable comprenant un analogue peptidique de l'hormone parathyroïdienne (PTH) dans une dose journalière suffisante pour obtenir un profil pharmacocinétique efficace et pour maintenir l'activité de l'adénylate cyclase, tout en réduisant simultanément les effets secondaires indésirables.
Also published as
CA2659846
EP2056862
JP2010501476
Latest bibliographic data on file with the International Bureau
# -